Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Sanderzon Mar 27, 2018 2:44pm
74 Views
Post# 27788811

RE:RE:I think

RE:RE:I think
Pandora wrote:
Sanderz wrote: people here overhyped this stock.  And before you read further, know that I DO have shares here, I bought shares in the early 0.50's I believe.    No doubt the last news release was a good milestone for this company.  I'm not knocking the company itself, but this stock was overhyped by the market, internet articles, and the people here.  If this drug is going to be SUCH A BIG DEAL, then this would be trading much much higher.  It may trade much higher further down the road, but not right now obviously.     People generally aren't stupid; if this was a BIG deal, it would be bought up much higher.


There is another aspirin alternative on nasdaq (PLXP) which I talked to Dan about. He felt the ATB346 is a better product but then he is also biased. PLXP was trading in the $6.50 area but recent quarterly results knocked it down to the $3.50 area. Wouldn't we like to even be there.




PLXP has approx. 30 million market cap and ATE's market cap is more than twice that,  So if anything, ATE might even be overvalued at this point..
Bullboard Posts